BioMarin Pharma (BMRN) Announces Completion of Acquisition of Inozyme (INZY) Jul 1, 2025 08:46AM
TD Cowen Downgrades Inozyme Pharma Inc. (INZY) to Hold Following Takeover May 16, 2025 04:18PM
Inozyme Pharma Inc. (INZY) May 2.5 calls, June 5 calls and December 2.5 calls active as share price up 178% May 16, 2025 03:44PM
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Inozyme Pharma, Inc. Buyout May 16, 2025 02:10PM
Jefferies Downgrades Inozyme Pharma Inc. (INZY) to Hold May 16, 2025 01:54PM


May 16, 2025 12:22PM Evercore ISI on BioMarin (BMRN): 'INZY Acquisition Looks Like a Solid Addition to the Growing and Often Overlooked Enzyme Therapy Biz'
May 16, 2025 07:32AM Inozyme Pharma Inc. (INZY) Halted, News Pending
May 16, 2025 07:31AM BioMarin Pharma (BMRN) Announces Acquisition of Inozyme Pharma (INZY) for $4 Per Share
May 14, 2025 07:31AM Inozyme Pharma, Inc. (INZY) Misses Q1 EPS by 4c
Apr 11, 2025 06:39AM H.C. Wainwright Reiterates Buy Rating on Inozyme Pharma Inc. (INZY)
Apr 10, 2025 08:31AM Inozyme Pharma (INZY) Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency
Mar 11, 2025 08:35AM Piper Sandler: 'We View Inozyme Pharma Inc. as a Diamond in the Rough'; PT Lowered
Mar 11, 2025 06:52AM H.C. Wainwright Reiterates Buy Rating on Inozyme Pharma Inc. (INZY)
Jan 13, 2025 05:26AM Inozyme Pharma Inc. (INZY) PT Lowered to $24 at Raymond James
Jan 10, 2025 08:06AM Inozyme Pharma (INZY) Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates
Dec 12, 2024 06:08AM Raymond James Starts Inozyme Pharma Inc. (INZY) at Buy
Nov 5, 2024 04:10PM Inozyme Pharma, Inc. (INZY) Tops Q3 EPS by 5c
Nov 5, 2024 03:05PM Inozyme Pharma Inc. (INZY) PT Raised to $43 at Piper Sandler
Oct 25, 2024 08:06AM H.C. Wainwright Reiterates Buy Rating on Inozyme Pharma Inc. (INZY)
Oct 25, 2024 07:27AM TD Cowen Reiterates Buy Rating on Inozyme Pharma Inc. (INZY)
Oct 24, 2024 01:15PM Inozyme Pharma (INZY) Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701
Oct 17, 2024 08:30AM Inozyme Pharma Inc. (INZY) Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial
Oct 7, 2024 08:30AM Inozyme Pharma Inc. (INZY) Appoints Erik Harris to its Board
Sep 11, 2024 04:07PM Stifel Starts Inozyme Pharma Inc. (INZY) at Buy
Aug 13, 2024 03:39AM Jefferies Assumes Inozyme Pharma Inc. (INZY) at Buy
Aug 6, 2024 09:45AM Inozyme Pharma, Inc. (INZY) Misses Q2 EPS by 4c
Jul 25, 2024 08:32AM Inozyme Pharma (INZY) Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function
Jul 3, 2024 06:44AM H.C. Wainwright Reiterates Buy Rating on Inozyme Pharma Inc. (INZY)
Jul 2, 2024 08:30AM Inozyme Pharma (INZY) Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency